

1 **Host genomics of the HIV-1 reservoir size and its decay rate during** 2 **suppressive antiretroviral treatment**

3
4 Christian W. Thorball^{1,*}, Alessandro Borghesi^{1,2,*}, Nadine Bachmann^{3,4}, Chantal von
5 Siebenthal^{3,4}, Valentina Vongrad^{3,4}, Teja Turk^{3,4}, Kathrin Neumann^{3,4}, Niko Beerenwinkel^{5,6},
6 Jasmina Bogojeska⁷, Volker Roth⁸, Yik Lim Kok^{3,4}, Sonali Parbhoo^{8,9}, Mario Wieser⁸, Jürg
7 Böni⁴, Matthieu Perreau¹⁰, Thomas Klimkait¹¹, Sabine Yerly¹², Manuel Battegay¹³, Andri
8 Rauch¹⁴, Patrick Schmid¹⁵, Enos Bernasconi¹⁶, Matthias Cavassini¹⁷, Roger D. Kouyos^{3,4},
9 Huldrych F. Günthard^{3,4}, Karin J. Metzner^{3,4}, Jacques Fellay^{1,18,§} and the Swiss HIV Cohort
10 Study

11
12 1 School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

13 2 Neonatal Intensive Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

14 3 Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich,
15 Zurich, Switzerland.

16 4 Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

17 5 Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.

18 6 SIB Swiss Institute of Bioinformatics, Basel, Switzerland.

19 7 IBM Research - Zurich, Rüschlikon, Switzerland.

20 8 Department of Mathematics and Computer Science, University of Basel, Basel, Switzerland.

21 9 Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University,
22 Cambridge, MA, USA.

23 10 Division of Immunology and Allergy, Lausanne University Hospital (CHUV) and
24 University of Lausanne, Lausanne, Switzerland.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 11 Division Infection Diagnostics, Department Biomedicine—Petersplatz, University of Basel,
26 Basel, Switzerland.

27 12 Division of Infectious Diseases and Laboratory of Virology, University Hospital Geneva,
28 University of Geneva, Geneva, Switzerland.

29 13 Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel,
30 Basel, Switzerland.

31 14 Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland.

32 15 Division of Infectious Diseases, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland.

33 16 Infectious Diseases Service, Regional Hospital of Lugano, Lugano, Switzerland.

34 17 Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, University of
35 Lausanne, Lausanne, Switzerland.

36 18 Precision Medicine Unit, Lausanne University Hospital (CHUV) and University of
37 Lausanne, Lausanne, Switzerland

38 * Equal contribution

39

40 **§ Corresponding author:**

41 Jacques Fellay

42 School of Life Sciences

43 École Polytechnique Fédérale de Lausanne

44 1015 Lausanne, Switzerland

45 E-mail: jacques.fellay@epfl.ch

46 Phone number: +41216931849

47

48

49 **Keywords:** HIV, genetics, ART, latent reservoir, GWAS, exome sequencing

50 **ABSTRACT**

51 **Introduction**

52 A major hurdle to HIV-1 eradication is the establishment of a latent viral reservoir early after
53 primary infection. Several factors are known to influence the HIV-1 reservoir size and decay
54 rate on suppressive antiretroviral treatment (ART), but little is known about the role of human
55 genetic variation.

56 **Methods**

57 We measured the reservoir size at three time points over a median of 5.4 years, and searched
58 for associations between human genetic variation and two phenotypic readouts: the reservoir
59 size at the first time point and its decay rate over the study period. We assessed the contribution
60 of common genetic variants using genome-wide genotyping data from 797 patients with
61 European ancestry enrolled in the Swiss HIV Cohort Study and searched for a potential impact
62 of rare variants and exonic copy number variants using exome sequencing data generated in a
63 subset of 194 study participants.

64 **Results**

65 Genome- and exome-wide analyses did not reveal any significant association with the size of
66 the HIV-1 reservoir or its decay rate on suppressive ART.

67 **Conclusions**

68 Our results point to a limited influence of human genetics on the size of the HIV-1 reservoir
69 and its long-term dynamics in successfully treated individuals.

70

71

72

73

74 INTRODUCTION

75 Combination antiretroviral treatment (ART) has turned the previously lethal infection by human
76 immunodeficiency virus type 1 (HIV-1) into a chronic disease. Despite this significant
77 achievement, HIV-1 as retrovirus, self-integrating its genome into the host chromosome,
78 persists indefinitely in infected individuals during treatment [1–4], and life-long ART is
79 required to control the infection.

80 A major hurdle to HIV-1 eradication is the establishment, already during primary infection, of
81 a latent viral reservoir of HIV-1 DNA persisting as provirus in resting memory CD4⁺ T cells
82 [1,2,5–8]. At the molecular level, chromatin remodeling, epigenetic modifications,
83 transcriptional interference, and availability of transcription factors have been considered as
84 possible mechanisms contributing to HIV-1 latency [9]. The viral reservoir is measurable
85 through different methods, including viral outgrowth assay and intracellular HIV-1 DNA
86 quantification [10,11]. Currently, there is no consensus on the best HIV-1 reservoir biomarker.
87 Total cell-associated HIV-1 DNA, easy to measure in different cell and tissue samples and
88 applicable to large populations, has been shown to be a good proxy for the reservoir size [12].
89 Indeed, while HIV-1 DNA measurement is able to detect both integrated and nonintegrated
90 viral genomes coding for intact or defective viruses [13], total HIV-1 DNA levels have been
91 shown to correlate with viral outgrowth [14], and to predict the time to viral rebound at
92 treatment interruption [15]. Moreover, the substantial loss of nonintegrated HIV-1 DNA
93 genomes following ART initiation suggests that total HIV-1 DNA after prolonged suppression
94 is largely accounted for by integrated viral genomes [16].

95 After an initial rapid decay following ART initiation, changes of the viral reservoir size over
96 time display wide inter-individual variability. By limiting dilution culture assay, the half-life of
97 the viral reservoir was first estimated to be 44 months (95% confidence interval 27.4-114.5) in
98 individuals with undetectable viremia [4]. A more recent study showed a slow decline of total

99 HIV-1 DNA with a half-life of 13 years after the first four years of suppressive ART [17].
100 Generally, different studies show a broad variability of the average decay rate, from 2.5 months
101 to no measurable decay [18–26]. One study even reported an increase in the viral reservoir size
102 in as much as 31% of patients in the 4-7 years following ART initiation [27], and recent data
103 from our group confirm this observation, reporting an increase in the reservoir size in 26.8% of
104 individuals in the 1.5-5.5 years after ART initiation [28].

105 Several factors are known to influence the decay rate of the viral reservoir: initiation of ART
106 during acute HIV-1 infection substantially accelerates the decay rate, while viral blips and low-
107 level viremia during ART slow it down, as shown in previous studies [22] and in recent data
108 from our cohort [28]. Conversely, treatment intensification, i.e. treating with additional drugs,
109 does not appear to influence the decay rate, suggesting that residual replication is not the main
110 driver of the viral reservoir [29] or that it may happen in sanctuary sites.

111 Human genetic variants have been shown to influence the outcome of various infections,
112 including HIV. Previous genome-wide association studies (GWAS) addressed the role of
113 common genetic polymorphisms in several HIV-related phenotypes, including plasma viral
114 load (HIV-1 RNA) at set point, exceptional capacity to control viral replication, pace of CD4+
115 T lymphocyte decline, time to clinical AIDS, rapid progressor status or long-term non-
116 progressor status (LTNP) [30–37], and, in one single study, the amount of intracellular HIV-1
117 DNA, measured at a single time point during the chronic phase of infection [38]. Rare genetic
118 variants that are detectable through DNA sequencing technologies have been investigated far
119 less. However, a large exome sequencing study did not reveal any convincing association of
120 such variants with the natural history of HIV disease [39].

121 To date, no studies have addressed the role of human genetic variation in determining the initial
122 viral reservoir size and the reservoir decay rate over time. In the current study, we searched for

123 host genetic factors associated with the HIV-1 reservoir size and its long-term dynamics in a
124 cohort of 797 HIV-1 positive individuals on suppressive ART for at least five years.

125

126

127 **METHODS**

128 **Ethics statement**

129 Participants in the Swiss HIV Cohort Study (SHCS) consented to the cohort study and genetic
130 analyses, as approved by the corresponding local Ethics Committees.

131

132 **Study participants**

133 The SHCS is an ongoing, nation-wide cohort study of HIV-positive individuals, including more
134 than 70% of all persons living with HIV in Switzerland. Clinical and laboratory information
135 has been prospectively recorded at follow-up visits every 3-6 months since 1988 [40]. The
136 general enrolment criteria have been described previously [28]. Additionally, availability of
137 genome-wide genotyping data from previous studies or of a DNA sample for genotyping was
138 required for inclusion in this study (Figure 1).

139

140 **Quantification of total HIV-1 DNA**

141 The collection of longitudinal cryopreserved peripheral blood mononuclear cells (PBMCs)
142 from eligible participants and the quantification of total HIV-1 DNA by droplet digital PCR has
143 been described previously along with the calculation of the reservoir decay rate [28]. Briefly,
144 this study utilized total HIV-1 DNA quantifications from three time points at a median of ~1.5
145 years, ~3.5 years, and ~5.4 years after initiation of ART.

146

147 **Genotyping and genome-wide association analyses**

148 Genome-wide genotyping data were obtained from previous GWAS that used various
149 microarrays, including the HumanCore-12, HumanHap550, Human610, Human1M and
150 Infinium CoreExome-24 BeadChips (Illumina Inc., San Diego, CA, USA), or generated from
151 DNA extracted from peripheral blood mononuclear cells using the HumanOmniExpress-24
152 BeadChip (Illumina Inc., San Diego, CA, USA).

153 Genotypes from each genotyping array were filtered and imputed separately, with variants first
154 flipped to the correct strand with BCFTOOLS (v1.8) according to the human GRCh37 reference
155 genome and filtered based on a less than 20% deviation from the 1000 genomes phase 3 EUR
156 reference panel. Genotypes were phased, and missing genotypes were imputed with EAGLE2
157 [41] and PBWT [42] respectively, using the 1000 Genomes Project Phase 3 reference panel on
158 the Sanger Imputation Service [43]. Study participants were filtered based on European
159 ancestry as determined by principal component analysis (PCA) using EIGENSTRAT (v6.1.4)
160 [44] and the HapMap project [45] as reference populations (Figure S1A). Imputed variants were
161 filtered by minor allele frequency (MAF) < 5%, missingness > 10%, deviation from Hardy-
162 Weinberg equilibrium ($P_{HWE} < 1e-6$) and imputation quality score (INFO < 0.8). The remaining
163 genotypes were then combined using PLINK (v1.90b5) [46] prior to analyses.

164 To carry out the GWASs, genome-wide genotypes were tested for association with each of the
165 two study phenotypes (reservoir size or reservoir decay rate) in two separate genome-wide
166 association analyses. Statistical significance was set to the standard genome-wide significance
167 threshold of $P < 5e-8$ to correct for multiple testing. The associations were computed using
168 linear mixed models with genetic relationship matrixes calculated between pairs of individuals
169 according to the leave-one-chromosome-out method as implemented in GCTA mlma-locu
170 (v1.91.4beta) [47,48], only including age and sex as covariates, to avoid masking of true
171 associations by confounders. To further assess the contribution of variables previously shown
172 to be associated with either reservoir size or decay rate, we ran multiple genome-wide

173 association analyses, each including age, sex, and one single covariate, for each of the two study
174 phenotypes. Finally, we conducted a GWAS including all the covariates except those showing
175 mutual correlations. These covariates included time on ART, time to viral suppression,
176 infection stage (acute or chronic), HIV-1 RNA pre-ART, last CD4+ T cell count pre-ART,
177 HIV-1 subtype, transmission group, and occurrence of blips or low-level viremia during
178 treatment.

179 Classical HLA alleles at the four-digit level and variable amino acids within HLA proteins were
180 imputed using SNP2HLA (v1.03) with the T1DGC reference panel consisting of 5,225
181 individuals of European ancestry [49]. Association analyses with the imputed HLA alleles and
182 multi-allelic amino acids was performed using linear regressions in PLINK and multivariate
183 omnibus tests, respectively. For all HLA analyses age, sex and the first principal component
184 was included as covariates.

185 Genotypes at specific loci, i.e. the CCR5 Δ 32 deletion (rs333) and the HLA-B*57:01 allele,
186 known to influence the setpoint viral load (spVL) [50,51], available from genome-wide
187 genotyping data, were tested for association with the reservoir size and its decay rate in 797
188 patients. High quality genotyping information on the CCR5 Δ 32 deletion was available for most
189 individuals (N = 687), while all had available HLA information.

190

191 **Exome sequencing and analysis**

192 All coding exons were captured using either the Illumina Truseq 65 Mb enrichment kit
193 (Illumina Inc., San Diego, CA, USA) or the IDT xGen Exome Research Panel v1.0 (Integrated
194 DNA Technologies Inc., Coralville, IA, USA) and sequenced on the Illumina HiSeq4000.
195 Sequence reads were aligned to the human reference genome (GRCh37) including decoys with
196 BWA-MEM (v0.7.10) [52]. PCR duplicates were flagged using Picard tools (v2.18.14) and
197 variant calling performed using GATK (v3.7) [53].

198 To ensure a high-quality variant set across capture kit batches, all samples were merged and
199 variants filtered based on sequencing depth ($DP \geq 20$) and genotype quality ($GQ \geq 30$) using
200 BCFTOOLS (v1.8). Furthermore, individual genotypes were set as missing in cases of low
201 depth ($DP < 10$) or low quality ($GQ < 20$). The effect of the included variants was annotated
202 with SnpEff (v4.3T) [54].

203 For single variant association analysis, the VCF file was converted to PLINK format using
204 BCFTOOLS and PLINK. Only variants with a MAF above 5%, missingness per variant below
205 5% and absence of severe deviation from Hardy-Weinberg equilibrium ($P_{HWE} > 1e-6$) were
206 retained for the subsequent association analyses using PLINK. Sex, age and the first principal
207 component were included as covariates. Only individuals of European descent were retained
208 for the analyses, as determined by PCA (Figure S1B).

209 The combined effect of rare protein-altering variants ($MAF < 5\%$), defined as either missense,
210 stop-gain, frameshift, essential splice variant or an indel by SnpEff, on the reservoir size and
211 decay rate was analyzed using optimal sequence kernel association tests (SKAT-O) [55]. For
212 the decay rate, individuals were split into two groups due to the non-normal distribution; one
213 exhibiting a very high decay over time ($< -0.03 -\log_{10}(DNA)$) and another with a stable
214 reservoir size (≥ -0.03 and $\leq 0.03 -\log_{10}(DNA)$). For this case-control analysis we used the
215 SKATbinary function with linear weighted variants as implemented in the SKAT R package.
216 In both cases, the analyses were adjusted for age, sex, and the first principal component.

217 Classical HLA class I and II alleles at the four-digit level were imputed from the exome
218 sequencing data using HLA*LA [56]. All reads mapping to the MHC region or marked as
219 unmapped were extracted using Samtools (v1.8) and used as input into HLA*LA. For
220 association analyses, the 4-digit HLA alleles were extracted and analyzed using PyHLA [57]
221 assuming an additive model, a minimum frequency of 5% and including age, sex and the first
222 principal component as covariates.

223

224 **Copy number variation**

225 Copy number variations (CNVs) were called from exome sequencing data using CLAMMS
226 [58]. CNVs were called for all samples in batches according to the exome capture kit used.
227 Within batches, samples were normalized based on coverage and potential intra-batch effects
228 adjusted for through the use of recommended mapping metrics extracted with Picard tools
229 (v2.18.14). After CNV calling, samples with the number of CNVs two times above the median
230 were excluded (N = 2). CNV association analyses were performed for duplications and
231 deletions separately for common CNVs (frequency > 5 %) with PLINK adjusting for age and
232 sex. Potential rare CNVs (frequency < 5%) impacting immune related genes were examined by
233 overlapping called CNVs with curated immune-related genes from Immpart [59] which were
234 also listed as protein coding in GENCODE (v25).

235

236 **Statistical analyses**

237 All statistical analyses were performed using the R statistical software (v3.5.2), unless
238 otherwise specified.

239

240

241 **RESULTS**

242 **Host genetic determinants of the reservoir size and long-term dynamics**

243 To investigate the effects of host genetic variation on the size of the HIV-1 reservoir 1.5 years
244 after ART initiation and its long-term dynamics under ART over a median duration of 5.4 years,
245 we performed a GWAS, including 797 well-characterized HIV-1 positive individuals. All study
246 participants were enrolled in the SHCS and were of European ancestry with longitudinal total
247 HIV-1 DNA measurements available (Table 1). The median HIV-1 reservoir size was 2.76

248 (IQR: 2.48-3.03) log₁₀ total HIV-1 DNA copies/1 million genomic equivalents measured ~1.5
249 years after initiation of ART (Figure S2A). The median decay rate between 1.5-5.4 years after
250 initiation of ART was -0.06 (IQR: -0.12-0.00) log₁₀ total HIV-1 DNA copies/1 million
251 genomic equivalents per year (Figure S2B). With our sample size we had 80% power to detect
252 variants with a MAF of 10% explaining at least 5% of the variance in HIV-1 reservoir size or
253 decay rate [60].

254 First, we performed GWAS using age and sex as covariates. We did not observe any genome-
255 wide significant variant ($P < 5e-8$) associated with either HIV-1 reservoir size or long-term
256 dynamics (Figure 2, S3). However, as we have previously determined, multiple factors are
257 associated with the HIV-1 reservoir size and its decay rate [28], some of which are correlated
258 (Figure S4). Thus, we performed additional analyses iteratively including these factors to test
259 whether they could mask genetic associations. We ran multiple GWAS each adjusting for age,
260 sex, plus one of the associated covariates, as well as all of the covariates together. The addition
261 of the covariates did not have any significant effect on the results nor the genome-wide inflation
262 factor (lambda) (Table S1).

263 Genetic variation in the HLA region has previously been associated with multiple HIV-related
264 outcomes, including spVL [51]. To test whether specific HLA variants were associated with
265 reservoir size or long-term dynamics, we imputed the HLA alleles and amino acids for all 797
266 individuals from the genotyping data. In line with the previous results, we did not observe any
267 genome-wide significant associations with any HLA allele or amino acid.

268

269 **Impact of protein-coding and rare variants**

270 To assess the impact of rare variants as well as protein-coding variants missed by genotyping
271 arrays on the HIV-1 reservoir size and long-term dynamics, we performed exome sequencing
272 in 194 of the 797 study participants. Patients were selected at the two extremes of the observed

273 reservoir decay rate: either very rapid, or absent (no change in reservoir size over ~5.4 years),
274 while individuals with increasing HIV-1 reservoir sizes were excluded (N=12). Thus, the long-
275 term dynamics phenotype was binarized for subsequent analyses of the decay rate, while the
276 HIV-1 reservoir size phenotype remained normally distributed (Figure S5).

277 To ensure that no common variants, missed by the genotype chips, were associated with the
278 HIV-1 reservoir size or long-term dynamics, we performed a GWAS for common variants using
279 age and sex as covariates. As with the genotyping data, we observed no genome-wide
280 significant variants for either phenotype (Figure S6).

281 We then examined the potential role of rare variants (MAF < 5%) with a functional impact
282 defined as either missense, frameshift, stop gained, splice acceptor or donor. Since HIV-1
283 primarily infects CD4+ T cells, we only included variants within genes expressed in these cells
284 as determined by Gutierrez-Arcelus *et al.* [61]. The significance threshold after correcting for
285 the number of tests performed was $P = 1.21e-5$. We did not observe any significant associations
286 for either the HIV-1 reservoir or the decay rate. The *AMBRA1* gene showed the strongest
287 association with HIV-1 reservoir size ($P = 4.15e-5$, not significant) (Figure S7).

288 To confirm the lack of HLA association seen with the genotyping data, we imputed the HLA
289 haplotypes from the exome data using HLA*LA. Again, we did not observe any significant
290 HLA association with the study outcomes.

291

292 **Copy number variations**

293 To examine the role of large exonic CNVs not captured by standard genotyping and exome
294 pipelines, we called CNVs from the mapped sequencing reads of the exome samples using the
295 software CLAMMS. The contribution of common CNVs to HIV-1 reservoir size and long-term
296 dynamics was analyzed by association analyses including age, sex and the first principal
297 component as covariates. No significant association was observed after Bonferroni correction

298 (Figure S8). We also searched for rare CNVs in curated immune-related genes from Immpart
299 [59] but did not discover any suggestive immune-related CNVs .

300

301 **Influence of HLA-B*57:01 and the CCR5 Δ 32 deletion on reservoir size and long-term** 302 **dynamics**

303 We have previously shown that pre-ART RNA viral load levels are associated with the HIV-1
304 reservoir size and the occurrence of blips [28]. The HLA-B*57:01 allele and the CCR5 Δ 32
305 deletion are well known genetic variants influencing HIV-1 spVL [50,51], and could thus also
306 be associated with the with the HIV-1 reservoir size or its decay rate. However, we did not
307 observe any nominal association (all $P > 0.05$) with either reservoir size or its long-term
308 dynamics for HLA-B*57:01 and CCR5 Δ 32 (Figure S9).

309

310

311 **DISCUSSION**

312 We used a combination of genomic technologies to assess the potential role of human genetic
313 factors in determining both the HIV-1 reservoir size and its long-term dynamics in a well-
314 characterized, population-based cohort. We studied 797 HIV-1-positive individuals of
315 European origin under suppressive ART over a median of 5.4 years, for whom extensive clinical
316 data are available, allowing detailed characterization and correction for potential confounders
317 [28]. We measured the HIV-1 reservoir size at three time points and selected two phenotypes
318 for our genomic study: the reservoir size at ~1.5 years after ART initiation and the slope of the
319 reservoir decay rate calculated over the three time points. Previous HIV host genetic studies
320 mostly focused on phenotypes reflecting the natural history of HIV-1 infection, prior to ART
321 initiation, including spontaneous viral control and disease progression [30–37]. A single study
322 specifically tested for associations between common genetic variants and the amount of

323 intracellular HIV-1 DNA, measured at a single time point during the chronic phase of infection
324 prior to initiation of any antiretroviral therapy [38]. Here, in contrast, we longitudinally assessed
325 samples collected from patients under suppressive ART to search for human genetic
326 determinants of the long-term dynamics of the HIV-1 reservoir during treatment.

327 We first conducted a GWAS on 797 individuals to test for association between common genetic
328 variants and the phenotypes. Given the small proportion of non-European subjects in the initial
329 study cohort, we only included patients of European ancestry to avoid any false positive
330 associations or masking of true positive associations due to different allele frequencies in small
331 proportions of individuals belonging to different subpopulations (Figure 1) [62]. Regardless of
332 including or not independent covariates other than the standard ones (i.e., sex and age), no
333 genetic variant reached the genome-wide significance threshold for association with any of the
334 two phenotypes. This may reflect a small effect size of genetic variants on the HIV-1 reservoir
335 size and decay rate. We acknowledge that a larger sample size and thus increased statistical
336 power may allow detecting genetic variants with a smaller effect size associated with the
337 phenotypes. However, it should be noted that this study is by far the largest today that has
338 investigated the size and decay of the HIV-reservoir in well characterized and well suppressed
339 HIV-positive individuals over a longer time period. Alternatively, the control of the HIV-1
340 reservoir size and its long-term dynamics may be under the control of viral or host factors other
341 than the individual germline genetic background. A previous report from our group had shown
342 a correlation between viral blips during the first 1.5 years of suppressive ART and the HIV-1
343 reservoir size 1.5 years after ART initiation, and between viral blips after 1.5-5.4 years of
344 suppressive ART or low-level viremia and a slower decay rate [28]. Importantly, viral blips are
345 generally thought to reflect transient increases in viral replication, and probably occur under
346 multifactorial influence from viral and host factors [63–70], with these latter possibly including,
347 but not being limited to, germline genetic variation. The biological relations between viral

348 reservoir, decay rate, viral blips, and the contribution of the individual genetic background still
349 need full elucidation.

350 Standard GWAS is designed to detect associations with common genetic variants (i.e., with a
351 MAF of at least 0.05), with little power to investigate the role of rare variants. Thus, to further
352 assess the contribution of rare variants in individuals at the extreme of the decay rate
353 distribution, we used exome sequencing in a selected subset of 194 study participants with very
354 high decay rate, or conversely, a stable reservoir size over time (Figure S5). Here again, our
355 analyses did not detect significant associations with the phenotypes. Although not reaching
356 statistical significance, a rare genetic variant with potential functional impact in *AMBRA1* had
357 a p-value for association just below the corrected threshold. The expression of *AMBRA1*, a core
358 component of the autophagy machinery, has previously been associated with long-term viral
359 control in HIV-1 non-progressors [71]. Future studies may further elucidate whether genetic
360 variation in *AMBRA1* may account for inter-individual differences in the long-term dynamics
361 of the HIV-1 reservoir.

362 Large deletions or duplications of genomic material may be implicated in human phenotypes,
363 with CNVs impacting the exonic regions being more likely to have a functional role. Thus, we
364 further investigated whether any common or rare CNV spanning exonic regions was associated
365 with the phenotype. Again, no CNV was statistically associated with the phenotypes both in
366 the exome-wide analyses and in analyses focused on immune-related genes.

367 An inherent limitation of our exome-based association analyses was their inability to detect rare
368 variants outside the coding or splice-site regions. The exonic regions account for approximately
369 1-2% of the whole human genome. Because many regulatory sequences are located in extra-
370 genic sites, our analysis did not fully investigate the role of highly conserved, non-coding
371 genetic regions in influencing the phenotypes linked to HIV-1 latency.

372 Additionally, we focused on specific genetic variants, i.e., the HLA haplotypes and the
373 CCR5 Δ 32 deletion, previously demonstrated to have a role in HIV-1 related phenotypes
374 [30,51]. Indeed, previous studies unraveled a robust association between variation in the HLA
375 region and the HIV-1 spVL [30]. Likewise, heterozygosity for the CCR5 Δ 32 deletion has been
376 shown to influence spontaneous HIV-1 control [51]. Thus, we imputed HLA genotypes from
377 genotyping and exome data, and studied the CCR5 Δ 32 deletion, without, however, detecting
378 any significant associations with the phenotypes or the covariates (Figure S9). Specifically, we
379 found no correlation between HLA genotypes and HIV-1 RNA plasma levels prior to ART
380 initiation, apparently contrasting with the previous findings of an association between HLA-
381 B*57:01 haplotype and spVL. This probably reflects historical changes in the therapeutic
382 approach following a diagnosis of HIV-1 infection, given that ART is currently initiated soon
383 after clinical diagnosis, before most patients reach a stable plateau of plasma viral load.
384 In our study, the quantification of the reservoir size at different time points may have been
385 influenced by factors as, for example, blips and low-level viremia, which may have reduced
386 our ability to detect significant genetic effects. It is also possible that, in the future, novel
387 methods to assess the viral reservoir will allow the detection of significant contributions of
388 genetic factors [72]. So far, it remains unanswered whether the initial response to acute
389 infection, the containment of ongoing replication, and the control of latently infected cells are
390 under the influence of the same or different molecular networks. It needs to be noted that in
391 previous work we have shown that host genetic factors as defined by GWAS did not explain
392 the severity of symptoms during acute HIV-infection, although severity of symptoms correlated
393 well with viral load and CD4 cell counts [73].
394 In conclusion, our study suggests that human individual germline genetic variation has little, if
395 any, influence on the control of the HIV-1 viral reservoir size and its long-term dynamics.
396 Complex, likely multifactorial biological processes govern HIV-1 viral persistence. Larger

397 studies will possibly clarify the role of common or rare genetic variants explaining small
398 proportions of the variability of the phenotypes related to viral latency.

399

400 **Data availability**

401 The datasets generated during and/or analyzed during the current study are not publicly
402 available due to privacy reasons, the sensitivities associated with HIV infections, and the
403 representativeness of the dataset, but is available on request.

404

405 **Conflicts of interest statement**

406 H.F.G. has received unrestricted research grants from Gilead Sciences and Roche; fees for data
407 and safety monitoring board membership from Merck; consulting/advisory board membership
408 fees from Gilead Sciences, ViiV, Merck, Sandoz and Mepha.

409 T.K. has received consulting/advisory board membership fees from Gilead Sciences and from
410 ViiV Healthcare for work that has no connection to the work presented here.

411 K.J.M. has received travel grants and honoraria from Gilead Sciences, Roche Diagnostics,
412 GlaxoSmithKline, Merck Sharp & Dohme, Bristol-Myers Squibb, ViiV and Abbott; and the
413 University of Zurich received research grants from Gilead Science, Roche, and Merck Sharp &
414 Dohme for studies that Dr. Metzner serves as principal investigator, and advisory board
415 honoraria from Gilead Sciences.

416 A.R. reports support to his institution for advisory boards and/or travel grants from MSD,
417 Gilead Sciences, Pfizer and Abbvie, and an investigator initiated trial (IIT) grant from Gilead
418 Sciences. All remuneration went to his home institution and not to A.R. personally, and all
419 remuneration was provided outside the submitted work.

420 All other authors declare no competing financial interests.

421

422 **Author contributions**

423 N.B., J.B., V.R., R.D.K., H.F.G., K.J.M., and J.F. contributed to the conception and design of
424 the study. C.v.S., V.V., K.N., Y.I.K., and K.J.M. contributed to the acquisition of data. A.B.,
425 C.W.T., N.B., T.T., S.P., M.W., R.D.K., and J.F. contributed to the analysis and interpretation
426 of data. J.B., M.P., T.K., S.Y., M.B., A.R., P.S., E.B., M.C., H.F.G., and the members of the
427 Swiss HIV Cohort Study (SHCS) conceived and managed the cohort, collected and contributed
428 patient samples and clinical data. A.B., C.W.T., and J.F. contributed to the drafting the article.
429 All authors read and approved the final manuscript.

430

431 **Acknowledgements**

432 We thank the patients for participating in the SHCS, the study nurses and physicians for
433 excellent patient care, A. Scherrer, A. Traytel, and S. Wild for excellent data management and
434 D. Perraudin and M. Amstutz for administrative assistance.

435

436 This work was funded within the framework of the Swiss HIV Cohort Study (SNF grant#
437 33CS30_177499 to H.F.G.). The data were gathered by the Five Swiss University Hospitals,
438 two Cantonal Hospitals, 15 affiliated hospitals and 36 private physicians (listed in
439 <http://www.shcs.ch/180-health-care-providers>). The work was furthermore supported by the
440 Systems.X grant # 51MRP0_158328 (to N.B., J.B., J.F., V.R., R.D.K., M.W., H.F.G. and
441 K.J.M.), by SNF grant 324730B_179571 (to H.F.G.), SNF grant SNF 310030_141067/1 (to
442 H.F.G. and K.J.M.), SNF grants no. PZ00P3-142411 and BSSGI0_155851 to R.D.K., the
443 Yvonne-Jacob Foundation (to H.F.G.), the University of Zurich's Clinical Research Priority
444 Program viral infectious disease, ZPHI (to H.F.G) and the Vontobel Foundation (to H.F.G. and
445 K.J.M.). M.W. is partially supported by the NCCR MARVEL, funded by the Swiss National
446 Science Foundation.

447

448 Members of the Swiss HIV Cohort Study:

449 Anagnostopoulos A, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A,
450 Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA,
451 Günthard HF (President of the SHCS), Haerry D (deputy of "Positive Council"), Hasse B,
452 Hirsch HH, Hoffmann M, Hösli I, Huber M, Kahlert CR (Chairman of the Mother & Child
453 Substudy), Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti
454 G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nicca D, Paioni P, Pantaleo G,
455 Perreau M, Rauch A (Chairman of the Scientific Board), Rudin C, Scherrer AU (Head of Data
456 Centre), Schmid P, Speck R, Stöckle M (Chairman of the Clinical and Laboratory
457 Committee), Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S.

458

459

460 REFERENCES

- 461 1. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al.
462 Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral
463 Therapy. *Science*. 1997 Nov 14;278(5341):1295–300.
- 464 2. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of
465 Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia.
466 *Science*. 1997 Nov 14;278(5341):1291–5.
- 467 3. Chun T-W, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, et al. Presence of an
468 inducible HIV-1 latent reservoir during highly active antiretroviral therapy. *Proc Natl*
469 *Acad Sci*. 1997 Nov 25;94(24):13193–7.
- 470 4. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term
471 follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4⁺
472 T cells. *Nat Med*. 2003 Jun;9(6):727–8.
- 473 5. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of
474 latent tissue reservoirs and total body viral load in HIV-1 infection. *Nature*. 1997 May
475 8;387(6629):183–8.
- 476 6. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool
477 of latently infected, resting CD4(+) T cells during primary HIV-1 infection. *Proc Natl*
478 *Acad Sci U S A*. 1998 Jul 21;95(15):8869–73.

- 479 7. Smith MZ, Wightman F, Lewin SR. HIV reservoirs and strategies for eradication. *Curr*
480 *HIV/AIDS Rep.* 2012 Mar;9(1):5–15.
- 481 8. Siliciano RF, Greene WC. HIV latency. *Cold Spring Harb Perspect Med.* 2011
482 Sep;1(1):a007096.
- 483 9. Ruelas DS, Greene WC. An integrated overview of HIV-1 latency. *Cell.* 2013 Oct
484 24;155(3):519–29.
- 485 10. Han Y, Wind-Rotolo M, Yang H-C, Siliciano JD, Siliciano RF. Experimental
486 approaches to the study of HIV-1 latency. *Nat Rev Microbiol.* 2007 Feb;5(2):95–106.
- 487 11. Hodel F, Patxot M, Snäkä T, Ciuffi A. HIV-1 latent reservoir: size matters. *Future Virol.*
488 2016 Dec;11(12):785–94.
- 489 12. Avettand-Fènoël V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A, et al. Total
490 HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications. *Clin*
491 *Microbiol Rev.* 2016 Oct;29(4):859–80.
- 492 13. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A
493 quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature.*
494 2019;566(7742):120–5.
- 495 14. Kiselina M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M,
496 Vandekerckhove L. Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth.
497 *PLoS Pathog.* 2016 Mar;12(3):e1005472.
- 498 15. Williams JP, Hurst J, Stöhr W, Robinson N, Brown H, Fisher M, et al. HIV-1 DNA
499 predicts disease progression and post-treatment virological control. *eLife.* 2014 Sep
500 12;3:e03821.
- 501 16. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Günthard HF, et al. Dynamics of
502 total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. *J Infect Dis.*
503 2008 Feb 1;197(3):411–9.
- 504 17. Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, et al.
505 Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of
506 inflammation or activation. *PLOS Pathog.* 2017 Apr 20;13(4):e1006285.
- 507 18. Zanchetta M, Walker S, Burighel N, Bellanova D, Rampon O, Giaquinto C, et al. Long-
508 term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active
509 antiretroviral therapy. *J Infect Dis.* 2006 Jun 15;193(12):1718–27.
- 510 19. Chun T-W, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, et al. Decay of
511 the HIV reservoir in patients receiving antiretroviral therapy for extended periods:
512 implications for eradication of virus. *J Infect Dis.* 2007 Jun 15;195(12):1762–4.
- 513 20. Strain MC, Günthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, et al.
514 Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic
515 stability predicts lifelong persistence. *Proc Natl Acad Sci U S A.* 2003 Apr
516 15;100(8):4819–24.

- 517 21. Izopet J, Salama G, Pasquier C, Sandres K, Marchou B, Massip P, et al. Decay of HIV-1
518 DNA in patients receiving suppressive antiretroviral therapy. *J Acquir Immune Defic*
519 *Syndr Hum Retrovirology Off Publ Int Retrovirology Assoc.* 1998 Dec 15;19(5):478–
520 83.
- 521 22. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the
522 latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of
523 residual viral replication during prolonged anti-retroviral therapy. *Nat Med.* 2000
524 Jan;6(1):82–5.
- 525 23. van Rij RP, van Praag RME, Prins JM, Rientsma R, Jurriaans S, Lange JMA, et al.
526 Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-
527 1 infection with a five-drug regimen. *Antivir Ther.* 2002 Mar;7(1):37–41.
- 528 24. Pires A, Hardy G, Gazzard B, Gotch F, Imami N. Initiation of antiretroviral therapy
529 during recent HIV-1 infection results in lower residual viral reservoirs. *J Acquir Immune*
530 *Defic Syndr* 1999. 2004 Jul 1;36(3):783–90.
- 531 25. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, et al. Effect of
532 treatment, during primary infection, on establishment and clearance of cellular reservoirs
533 of HIV-1. *J Infect Dis.* 2005 May 1;191(9):1410–8.
- 534 26. Fischer M, Joos B, Niederöst B, Kaiser P, Hafner R, von Wyl V, et al. Biphasic decay
535 kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during
536 antiretroviral therapy. *Retrovirology.* 2008 Nov 26;5:107.
- 537 27. Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, et al. HIV-1 DNA
538 decay dynamics in blood during more than a decade of suppressive antiretroviral
539 therapy. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2014 Nov;59(9):1312–21.
- 540 28. Bachmann N, Siebenthal C von, Vongrad V, Turk T, Neumann K, Beerenwinkel N, et
541 al. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive
542 ART. *Nat Commun.* 2019 Jul 19;10(1):1–11.
- 543 29. International AIDS Society Scientific Working Group on HIV Cure, Deeks SG, Autran
544 B, Berkhout B, Benkirane M, Cairns S, et al. Towards an HIV cure: a global scientific
545 strategy. *Nat Rev Immunol.* 2012 20;12(8):607–14.
- 546 30. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-
547 genome association study of major determinants for host control of HIV-1. *Science.*
548 2007 Aug 17;317(5840):944–7.
- 549 31. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, et al. Common
550 genetic variation and the control of HIV-1 in humans. *PLoS Genet.* 2009
551 Dec;5(12):e1000791.
- 552 32. Pelak K, Goldstein DB, Walley NM, Fellay J, Ge D, Shianna KV, et al. Host
553 determinants of HIV-1 control in African Americans. *J Infect Dis.* 2010 Apr
554 15;201(8):1141–9.

- 555 33. International HIV Controllers Study, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker
556 PIW, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide
557 presentation. *Science*. 2010 Dec 10;330(6010):1551–7.
- 558 34. Herbeck JT, Gottlieb GS, Winkler CA, Nelson GW, An P, Maust BS, et al. Multistage
559 genomewide association study identifies a locus at 1q41 associated with rate of HIV-1
560 disease progression to clinical AIDS. *J Infect Dis*. 2010 Feb 15;201(4):618–26.
- 561 35. Le Clerc S, Limou S, Coulonges C, Carpentier W, Dina C, Taing L, et al. Genomewide
562 association study of a rapid progression cohort identifies new susceptibility alleles for
563 AIDS (ANRS Genomewide Association Study 03). *J Infect Dis*. 2009 Oct
564 15;200(8):1194–201.
- 565 36. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, Delaneau O, et al.
566 Genomewide association study of an AIDS-nonprogression cohort emphasizes the role
567 played by HLA genes (ANRS Genomewide Association Study 02). *J Infect Dis*. 2009
568 Feb 1;199(3):419–26.
- 569 37. Limou S, Coulonges C, Herbeck JT, van Manen D, An P, Le Clerc S, et al. Multiple-
570 cohort genetic association study reveals CXCR6 as a new chemokine receptor involved
571 in long-term nonprogression to AIDS. *J Infect Dis*. 2010 Sep 15;202(6):908–15.
- 572 38. Dalmaso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix M-L, et al. Distinct
573 genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection:
574 the ANRS Genome Wide Association 01 study. *PLoS One*. 2008;3(12):e3907.
- 575 39. McLaren PJ, Pulit SL, Gurdasani D, Bartha I, Shea PR, Pomilla C, et al. Evaluating the
576 Impact of Functional Genetic Variation on HIV-1 Control. *J Infect Dis*. 2017
577 27;216(9):1063–9.
- 578 40. Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Günthard HF, Telenti A, et
579 al. Cohort Profile: The Swiss HIV Cohort Study. *Int J Epidemiol*. 2010 Oct
580 1;39(5):1179–89.
- 581 41. Loh P-R, Danecek P, Palamara PF, Fuchsberger C, Reshef YA, Finucane HK, et al.
582 Reference-based phasing using the Haplotype Reference Consortium panel. *Nat Genet*.
583 2016 Nov;48(11):1443–8.
- 584 42. Durbin R. Efficient haplotype matching and storage using the positional Burrows-
585 Wheeler transform (PBWT). *Bioinformatics*. 2014 May 1;30(9):1266–72.
- 586 43. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A
587 reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* [Internet].
588 2016 Aug 22 [cited 2016 Aug 31];advance online publication. Available from:
589 <http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.3643.html>
- 590 44. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal
591 components analysis corrects for stratification in genome-wide association studies. *Nat*
592 *Genet*. 2006 Aug;38(8):904–9.
- 593 45. The International HapMap 3 Consortium. Integrating common and rare genetic variation
594 in diverse human populations. *Nature*. 2010 Sep;467(7311):52–8.

- 595 46. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
596 PLINK: rising to the challenge of larger and richer datasets. *GigaScience*. 2015 Dec
597 1;4(1):1–16.
- 598 47. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A Tool for Genome-wide Complex
599 Trait Analysis. *Am J Hum Genet*. 2011 Jan 7;88(1):76–82.
- 600 48. Yang J, Zaitlen NA, Goddard ME, Visscher PM, Price AL. Advantages and pitfalls in
601 the application of mixed-model association methods. *Nat Genet*. 2014 Feb;46(2):100–6.
- 602 49. Jia X, Han B, Onengut-Gumuscu S, Chen W-M, Concannon PJ, Rich SS, et al. Imputing
603 Amino Acid Polymorphisms in Human Leukocyte Antigens. *PLOS ONE*. 2013 Jun
604 6;8(6):e64683.
- 605 50. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A Whole-
606 Genome Association Study of Major Determinants for Host Control of HIV-1. *Science*.
607 2007 Aug 17;317(5840):944–7.
- 608 51. McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, et al.
609 Polymorphisms of large effect explain the majority of the host genetic contribution to
610 variation of HIV-1 virus load. *Proc Natl Acad Sci*. 2015 Nov 24;112(47):14658–63.
- 611 52. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler
612 transform. *Bioinforma Oxf Engl*. 2009 Jul 15;25(14):1754–60.
- 613 53. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytzky A, et al. The
614 Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation
615 DNA sequencing data. *Genome Res*. 2010 Sep 1;20(9):1297–303.
- 616 54. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et al. A program for
617 annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs
618 in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin)*. 2012
619 Jun;6(2):80–92.
- 620 55. Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, et al. Optimal
621 unified approach for rare-variant association testing with application to small-sample
622 case-control whole-exome sequencing studies. *Am J Hum Genet*. 2012 Aug
623 10;91(2):224–37.
- 624 56. Dilthey AT, Gourraud P-A, Mentzer AJ, Cereb N, Iqbal Z, McVean G. High-Accuracy
625 HLA Type Inference from Whole-Genome Sequencing Data Using Population
626 Reference Graphs. *PLOS Comput Biol*. 2016 Oct 28;12(10):e1005151.
- 627 57. Fan Y, Song Y-Q. PyHLA: tests for the association between HLA alleles and diseases.
628 *BMC Bioinformatics*. 2017 Feb 6;18(1):90.
- 629 58. Packer JS, Maxwell EK, O’Dushlaine C, Lopez AE, Dewey FE, Chernomorsky R, et al.
630 CLAMMS: a scalable algorithm for calling common and rare copy number variants from
631 exome sequencing data. *Bioinformatics*. 2016 Jan 1;32(1):133–5.

- 632 59. Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, et al. ImmPort,
633 toward repurposing of open access immunological assay data for translational and
634 clinical research. *Sci Data*. 2018 27;5:180015.
- 635 60. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and
636 association genetic mapping studies of complex traits. *Bioinformatics*. 2003 Jan
637 1;19(1):149–50.
- 638 61. Gutierrez-Arcelus M, Teslovich N, Mola AR, Polidoro RB, Nathan A, Kim H, et al.
639 Lymphocyte innateness defined by transcriptional states reflects a balance between
640 proliferation and effector functions. *Nat Commun*. 2019 Feb 8;10(1):1–15.
- 641 62. Marees AT, de Kluiver H, Stringer S, Vorspan F, Curis E, Marie-Claire C, et al. A
642 tutorial on conducting genome-wide association studies: Quality control and statistical
643 analysis. *Int J Methods Psychiatr Res*. 2018;27(2):e1608.
- 644 63. Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir
645 replenishment in HIV-infected patients on antiretroviral therapy. *J Acquir Immune Defic
646 Syndr* 1999. 2007 Aug 15;45(5):483–93.
- 647 64. Fletcher CV, Staskus K, Wietgreffe SW, Rothenberger M, Reilly C, Chipman JG, et al.
648 Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations
649 in lymphatic tissues. *Proc Natl Acad Sci U S A*. 2014 Feb 11;111(6):2307–12.
- 650 65. Lorenzo-Redondo R, Fryer HR, Bedford T, Kim E-Y, Archer J, Pond SLK, et al.
651 Persistent HIV-1 replication maintains the tissue reservoir during therapy. *Nature*. 2016
652 Feb 4;530(7588):51–6.
- 653 66. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to
654 antiretroviral therapy observed prior to transient human immunodeficiency virus type 1
655 viremia. *J Infect Dis*. 2007 Dec 15;196(12):1773–8.
- 656 67. Young J, Rickenbach M, Calmy A, Bernasconi E, Staehelin C, Schmid P, et al. Transient
657 detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort
658 Study. *BMC Infect Dis*. 2015 Sep 21;15:382.
- 659 68. Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, et al. Clonally
660 expanded CD4+ T cells can produce infectious HIV-1 in vivo. *Proc Natl Acad Sci U S
661 A*. 2016 Feb 16;113(7):1883–8.
- 662 69. Wang Z, Gurule EE, Brennan TP, Gerold JM, Kwon KJ, Hosmane NN, et al. Expanded
663 cellular clones carrying replication-competent HIV-1 persist, wax, and wane. *Proc Natl
664 Acad Sci U S A*. 2018 13;115(11):E2575–84.
- 665 70. Lee GQ, Orlova-Fink N, Einkauf K, Chowdhury FZ, Sun X, Harrington S, et al. Clonal
666 expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. *J Clin
667 Invest*. 2017 Jun 30;127(7):2689–96.
- 668 71. Nardacci R, Amendola A, Ciccocanti F, Corazzari M, Esposito V, Vlassi C, et al.
669 Autophagy plays an important role in the containment of HIV-1 in nonprogressor-
670 infected patients. *Autophagy*. 2014 Jul;10(7):1167–78.

- 671 72. Gaebler C, Lorenzi JCC, Oliveira TY, Nogueira L, Ramos V, Lu C-L, et al.
672 Combination of quadruplex qPCR and next-generation sequencing for qualitative and
673 quantitative analysis of the HIV-1 latent reservoir. *J Exp Med*. 2019 Oct
674 7;216(10):2253–64.
- 675 73. Braun DL, Kouyos R, Oberle C, Grube C, Joos B, Fellay J, et al. A novel Acute
676 Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1
677 disease progression. *PloS One*. 2014;9(12):e114111.

678

679

680 **FIGURE LEGENDS**

681 **Figure 1.** Patient selection flowchart. Specific inclusion and exclusion criteria are listed for
682 each selection step. ART (antiretroviral therapy); PBMCs (peripheral blood mononuclear cells);
683 PI (protease inhibitor); PCA (principal component analysis).

684

685 **Figure 2.** Association results with HIV-1 reservoir size. Manhattan plot with association p-
686 values ($-\log_{10}(P)$) per genetic variant plotted by genomic position. Dashed line indicates the
687 threshold for genome-wide significance ($P = 5e-8$). No variants were found to be genome-wide
688 significant.

689

690

691

692

693

694

695

696

697

698

699 **TABLES**

Table 1. Patient characteristics	
Total number of individuals	
Genotyped	797
Genotyped + exome sequenced	194
Age at first HIV-1 DNA sample in years	
median (IQR)	44 (38, 50)
Sex	
Female	123 (15.4%)
Male	674 (84.6%)
Transmission group	
HET	241 (30.2%)
IDU	77 (9.7%)
MSM	448 (56.2%)
Other	31 (3.9%)
HIV-1 subtype	
B	550 (69.0%)
Non-B	128 (16.1%)
Unknown	119 (14.9%)
Occurrence of blips or low-level viremia	
Blips	200 (25.1%)
Low-level viremia	68 (8.5%)
None	529 (66.4%)
Time on ART	
median (IQR)	1.50 (1.28, 1.69)
Infection stage	
Acute	140 (17.6%)
Chronic	657 (82.4%)
Time to viral suppression	
median (IQR)	0.34 (0.23, 0.51)
Log₁₀ HIV-1 plasma RNA pre-ART per mL	
median (IQR)	480 (248, 684)
CD4+ cell count pre-ART cells/μL blood	
median (IQR)	186 (90, 270)
HIV-1 reservoir size	
median (IQR)	2.76 (2.48, 3.03)
HIV-1 reservoir decay rate	
median (IQR)	-0.06 (-0.12, -0.00)

700 Transmission group indicates the self-reported route of infection (heterosexual (HET),
 701 intravenous drug usage (IDU), men who have sex with men (MSM), and other (including
 702 transfusions and unknown)). The occurrence of viral blips was defined by measurements of \geq

703 50 HIV-1 RNA copies/mL plasma within a 30-day window. Individuals with consecutive
704 measurements of ≥ 50 HIV-1 RNA copies/mL plasma for longer durations were classified as
705 exhibiting low-level viremia. Time to viral suppression was the time from initiation of ART to
706 the first viral load measurement below 50 copies/mL HIV-1 plasma RNA. HIV-1 reservoir size
707 was measured in \log_{10} total HIV-1 DNA/1 million genomic equivalents ~ 1.5 years after
708 initiating ART. The HIV-1 reservoir decay rate was based on the three measurements of total
709 HIV-1 DNA levels taken at the median of 1.5, 3.5 and 5.4 years after initiation of ART.

Figure 1




Figure 2

